Volume 14 Issue 3
May  2023
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2023  >  14(3): 364-370
Wang Jiaqi, Sheng Xinge, Ma Zhihao, et al. Prevention and treatment of high-risk acute myeloid leukemia recurrence after allogeneic hematopoietic stem cell transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 364-370. doi: 10.3969/j.issn.1674-7445.2023.03.007
Citation: Wang Jiaqi, Sheng Xinge, Ma Zhihao, et al. Prevention and treatment of high-risk acute myeloid leukemia recurrence after allogeneic hematopoietic stem cell transplantation[J]. ORGAN TRANSPLANTATION, 2023, 14(3): 364-370. doi: 10.3969/j.issn.1674-7445.2023.03.007
shu

Prevention and treatment of high-risk acute myeloid leukemia recurrence after allogeneic hematopoietic stem cell transplantation

doi: 10.3969/j.issn.1674-7445.2023.03.007

  • Graduate School of Xiamen University Medical College, Xiamen 361102, China

More Information
  • Corresponding author: Lu Quanyi, Email: quanyilu@hotmail.com
  • Received Date: 2022-11-01
  • Publish Date: 2023-05-15
    Abstract
  • Acute myeloid leukemia (AML) is a group of highly-heterogeneous clonal diseases. Chemotherapy and hematopoietic stem cell transplantation are considered as effective treatment for AML. For high-risk AML patients, allogeneic hematopoietic stem cell transplantation is an effective therapeutic option. However, some AML patients may still face the problem of disease recurrence after hematopoietic stem cell transplantation. A majority of recurrent patients cannot be effectively treated by chemotherapy or secondary transplantation, which is the main cause of death after allogeneic hematopoietic stem cell transplantation. Therefore, it is of significance to strengthen follow-up of AML patients after allogeneic hematopoietic stem cell transplantation and implement appropriate measures to prevent postoperative recurrence. In this article, the monitoring, drug prevention and cell therapy of recurrence after allogeneic hematopoietic stem cell transplantation in high-risk AML patients were reviewed, aiming to provide reference for improving clinical prognosis of high-risk AML patients undergoing allogeneic hematopoietic stem cell transplantation.

     

    • FullText(HTML)
  • loading
    • References(43)
  • [1]
    LOKE J, BUKA R, CRADDOCK C. Allogeneic stem cell transplantation for acute myeloid leukemia: who, when, and how?[J]. Front Immunol, 2021, 12: 659595. DOI: 10.3389/fimmu.2021.659595.
    [2]
    XUAN L, LIU Q. Maintenance therapy in acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation[J]. J Hematol Oncol, 2021, 14(1): 4. DOI: 10.1186/s13045-020-01017-7.
    [3]
    BEJANYAN N, WEISDORF DJ, LOGAN BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study[J]. Biol Blood Marrow Transplant, 2015, 21(3): 454-459. DOI: 10.1016/j.bbmt.2014.11.007.
    [4]
    YANADA M, KONUMA T, YAMASAKI S, et al. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes[J]. Bone Marrow Transplant, 2021, 56(5): 1126-1133. DOI: 10.1038/s41409-020-01163-z.
    [5]
    KATO K. Treatment approach for relapse of adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation[J]. Rinsho Ketsueki, 2021, 62(5): 505-511. DOI: 10.11406/rinketsu.62.505.
    [6]
    KUNADT D, STÖLZEL F. Effective immunosurveillance after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia[J]. Cancer Manag Res, 2021, 13: 7411-7427. DOI: 10.2147/CMAR.S261721.
    [7]
    KREIDIEH F, ABOU DALLE I, MOUKALLED N, et al. Relapse after allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia: an overview of prevention and treatment[J]. Int J Hematol, 2022, 116(3): 330-340. DOI: 10.1007/s12185-022-03416-7.
    [8]
    AITKEN MJL, RAVANDI F, PATEL KP, et al. Prognostic and therapeutic implications of measurable residual disease in acute myeloid leukemia[J]. J Hematol Oncol, 2021, 14(1): 137. DOI: 10.1186/s13045-021-01148-5.
    [9]
    MAFFINI E, LABOPIN M, BEELEN DW, et al. Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)[J]. Bone Marrow Transplant, 2022, 57(10): 1556-1563. DOI: 10.1038/s41409-022-01748-w.
    [10]
    VONK CM, AL HINAI ASA, HANEKAMP D, et al. Molecular minimal residual disease detection in acute myeloid leukemia[J]. Cancers (Basel), 2021, 13(21): 5431. DOI: 10.3390/cancers13215431.
    [11]
    张静, 王宗慧. 白血病与淋巴瘤的微小残留病检测手段前景及临床意义探讨[J]. 现代肿瘤医学, 2022, 30(21): 4009-4013. DOI: 10.3969/j.issn.1672-4992.2022.21.037.

    ZHANG J, WANG ZH. Prospects and clinical significance of detection methods for minimal residual disease in the field of leukemia and lymphoma[J]. J Mod Oncol, 2022, 30(21): 4009-4013. DOI: 10.3969/j.issn.1672-4992.2022.21.037.
    [12]
    DÖHNER H, ESTEY E, GRIMWADE D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel[J]. Blood, 2017, 129(4): 424-447. DOI: 10.1182/blood-2016-08-733196.
    [13]
    IVEY A, HILLS RK, SIMPSON MA, et al. Assessment of minimal residual disease in standard-risk AML[J]. N Engl J Med, 2016, 374(5): 422-433. DOI: 10.1056/NEJMoa1507471.
    [14]
    ALI N, TOMLINSON B, PATEL RD, et al. Role of post-allogeneic hematopoietic stem cell transplantation low-dose azacitidine for prevention of relapse in patients with acute myeloid leukemia and myelodysplastic syndrome: a retrospective analysis[J]. Biol Blood Marrow Transplant, 2020, 26(3): S126-S127. DOI: 10.1016/j.bbmt.2019.12.643.
    [15]
    PLATZBECKER U, MIDDEKE JM, SOCKEL K, et al. Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial[J]. Lancet Oncol, 2018, 19(12): 1668-1679. DOI: 10.1016/S1470-2045(18)30580-1.
    [16]
    GUILLAUME T, MALARD F, MAGRO L, et al. Prospective phase Ⅱ study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Bone Marrow Transplant, 2019, 54(11): 1815-1826. DOI: 10.1038/s41409-019-0536-y.
    [17]
    LIBERATORE C, STANGHELLINI MTL, LORENTINO F, et al. Azacitidine and donor lymphocytes infusions in acute myeloid leukemia and myelodysplastic syndrome relapsed after allogeneic hematopoietic stem cell transplantation from alternative donors[J]. Ther Adv Hematol, 2022, 13: 20406207221090882. DOI: 10.1177/20406207221090882.
    [18]
    GUO WW, SU XH, WANG MY, et al. Regulatory T cells in GVHD therapy[J]. Front Immunol, 2021, 12: 697854. DOI: 10.3389/fimmu.2021.697854.
    [19]
    GROVER P, GOEL PN, GREENE MI. Regulatory T cells: regulation of identity and function[J]. Front Immunol, 2021, 12: 750542. DOI: 10.3389/fimmu.2021.750542.
    [20]
    GOODYEAR OC, DENNIS M, JILANI NY, et al. Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML)[J]. Blood, 2012, 119(14): 3361-3369. DOI: 10.1182/blood-2011-09-377044.
    [21]
    GAO L, ZHANG Y, WANG S, et al. Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: an open-label, multicenter, randomized controlled trial[J]. J Clin Oncol, 2020, 38(36): 4249-4259. DOI: 10.1200/JCO.19.03277.
    [22]
    ROMAN-GOMEZ J, JIMENEZ-VELASCO A, CASTILLEJO JA, et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia[J]. Blood, 2004, 104(8): 2492-2498. DOI: 10.1182/blood-2004-03-0954.
    [23]
    刘佳. 小剂量地西他滨联合丙戊酸用于急性白血病/骨髓增生异常综合征异基因造血干细胞移植后维持治疗[D]. 郑州: 郑州大学, 2019.
    [24]
    WU M, LI C, ZHU X. FLT3 inhibitors in acute myeloid leukemia[J]. J Hematol Oncol, 2018, 11(1): 133. DOI: 10.1186/s13045-018-0675-4.
    [25]
    HUANG Y, HU J, LU T, et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis[J]. Cancer Manag Res, 2019, 11: 4129-4142. DOI: 10.2147/CMAR.S194523.
    [26]
    ANTAR AI, OTROCK ZK, JABBOUR E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J]. Leukemia, 2020, 34(3): 682-696. DOI: 10.1038/s41375-019-0694-3.
    [27]
    XUAN L, WANG Y, HUANG F, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial[J]. Lancet Oncol, 2020, 21(9): 1201-1212. DOI: 10.1016/S1470-2045(20)30455-1.
    [28]
    BURCHERT A, BUG G, FRITZ LV, et al. Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)[J]. J Clin Oncol, 2020, 38(26): 2993-3002. DOI: 10.1200/JCO.19.03345.
    [29]
    SANDMAIER BM, KHALED S, ORAN B, et al. Results of a phase 1 study of quizartinib (AC220) as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic cell transplantation[J]. Blood, 2014, 124(21): 428. DOI: 10.1182/blood.v124.21.428.428.
    [30]
    DUCHMANN M, MICOL JB, DUPLOYEZ N, et al. Prognostic significance of concurrent gene mutations in intensively treated patients with IDH-mutated AML: an ALFA study[J]. Blood, 2021, 137(20): 2827-2837. DOI: 10.1182/blood.2020010165.
    [31]
    DINARDO CD, STEIN EM, DE BOTTON S, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML[J]. N Engl J Med, 2018, 378(25): 2386-2398. DOI: 10.1056/NEJMoa1716984.
    [32]
    STEIN EM, DINARDO CD, POLLYEA DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia[J]. Blood, 2017, 130(6): 722-731. DOI: 10.1182/blood-2017-04-779405.
    [33]
    刘艺, 裴仁治. Bcl-2抑制剂维奈托克在较高危组骨髓增生异常综合征中的治疗进展[J]. 实用医学杂志, 2022, 38(16): 2106-2109. DOI: 10.3969/j.issn.1006-5725.2022.16.023.

    LIU Y, PEI RZ. Advances of Bcl-2 inhibitor venetoclaxfor higher-risk groups of myelodysplastic syndromes[J]. J Pract Med, 2022, 38(16): 2106-2109. DOI: 10.3969/j.issn.1006-5725.2022.16.023.
    [34]
    ZHAO P, NI M, MA D, et al. Venetoclax plus azacitidine and donor lymphocyte infusion in treating acute myeloid leukemia patients who relapse after allogeneic hematopoietic stem cell transplantation[J]. Ann Hematol, 2022, 101(1): 119-130. DOI: 10.1007/s00277-021-04674-x.
    [35]
    SERPENTI F, SCIUMÈ M, GALASSI G, et al. Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse[J]. Leuk Lymphoma, 2022, 63(11): 2743-2746. DOI: 10.1080/10428194.2022.2090553.
    [36]
    WEI Y, XIONG X, LI X, et al. Low-dose decitabine plus venetoclax is safe and effective as post-transplant maintenance therapy for high-risk acute myeloid leukemia and myelodysplastic syndrome[J]. Cancer Sci, 2021, 112(9): 3636-3644. DOI: 10.1111/cas.15048.
    [37]
    KENT A, POLLYEA DA, WINTERS A, et al. Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse[J]. Blood, 2020, 136(Suppl 1): 11-12. DOI: 10.1182/blood-2020-138832.
    [38]
    KENT A, VASU S, SCHATZ D, et al. Glasdegib as maintenance therapy for patients with AML and MDS patients at high risk for postallogeneic stem cell transplant relapse[J]. Blood Adv, 2020, 4(13): 3102-3108. DOI: 10.1182/bloodadvances.2020001991.
    [39]
    HARADA K, MIZUNO S, YANO S, et al. Donor lymphocyte infusion after haploidentical hematopoietic stem cell transplantation for acute myeloid leukemia[J]. Ann Hematol, 2022, 101(3): 643-653. DOI: 10.1007/s00277-021-04731-5.
    [40]
    YAN CH, LIU QF, WU DP, et al. Prophylactic donor lymphocyte infusion (DLI) followed by minimal residual disease and graft-versus-host disease-guided multiple dlis could improve outcomes after allogeneic hematopoietic stem cell transplantation in patients with refractory/relapsed acute leukemia[J]. Biol Blood Marrow Transplant, 2017, 23(8): 1311-1319. DOI: 10.1016/j.bbmt.2017.04.028.
    [41]
    LULLA PD, NAIK S, VASILEIOU S, et al. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant[J]. Blood, 2021, 137(19): 2585-2597. DOI: 10.1182/blood.2020009471.
    [42]
    GUILLAUME T, THÉPOT S, PETERLIN P, et al. Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome[J]. Transplant Cell Ther, 2021, 27(10): 839. e1-839. e6. DOI: 10.1016/j.jtct.2021.06.029.
    [43]
    SHEN X, PAN J, QI C, et al. Impact of pre-transplantation minimal residual disease (MRD) on the outcome of allogeneic hematopoietic stem cell transplantation for acute leukemia[J]. Hematology, 2021, 26(1): 295-300. DOI: 10.1080/16078454.2021.1889162.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (298) PDF downloads(54) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return